Lupin Somerset is recalling approximately 46,700 bottles of Morphine Sulfate Extended-Release tablets in 15 mg, 30 mg, 60 mg, 100 mg, and 200 mg strengths. The recall was initiated because the medication failed to meet required specifications for impurities and degradation during testing. This prescription drug is used for pain management and was distributed nationwide to five wholesalers and one supermarket chain. If you have this medication, you should consult your healthcare provider or pharmacist regarding the safety of your current supply.
The tablets failed to meet quality standards for impurities and degradation, which means the medication may contain higher-than-allowed levels of unintended chemical compounds or may have lost potency over time. While the risk is categorized as low, impurities in prescription medications can potentially affect how the drug works or cause unexpected side effects.
Healthcare provider consultation and pharmacy refund.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.